Health policy and government relations represent one of the most strategically consequential domains for any pharmaceutical company. Legislative changes, regulatory guidances, reimbursement policy shifts, and drug pricing reforms can profoundly affect a company’s revenue, pipeline value, and ability to operate. At the same time, building credible government relations capability requires sustained relationship investment, technical policy expertise, and organizational alignment across multiple functions.
For pharma CEOs, the challenge is maintaining genuine strategic influence in policy environments while ensuring that day-to-day government relations work is managed by a capable and well-resourced team. This article outlines delegation strategies that help pharma CEOs maintain appropriate strategic engagement without becoming personally involved in the operational dimensions of lobbying, regulatory policy engagement, and legislative advocacy.
Understanding the Scope of Health Policy and Government Relations
Government relations in pharma encompasses a broader set of activities than many executives initially appreciate:
Federal legislative affairs covers engagement with Congress on legislation affecting drug pricing, Medicare and Medicaid reimbursement, FDA authorization, and healthcare reform.
FDA and regulatory agency engagement covers the company’s relationship with the FDA on matters beyond individual product submissions: guidance development, regulatory science policy, user fee negotiations, and senior FDA leadership relationships.
State government relations covers engagement with state legislatures and executive agencies on matters including state Medicaid programs, drug pricing transparency laws, and pharmacy regulations.
International government relations covers engagement with health authorities, government health ministries, and legislative bodies in the company’s key international markets.
Trade association engagement covers participation in PhRMA, BIO, and other industry associations that advocate on policy matters of collective concern.
Policy research and analysis covers the internal capability to monitor, analyze, and respond to policy developments across all of these domains.
The CEO’s Strategic Role in Health Policy
The CEO is not a lobbyist and should not be managed like one. But the CEO is the company’s most credible external representative on strategic policy matters, and well-timed CEO engagement with senior policymakers, congressional leaders, and administration officials can move outcomes that staff-level government relations work cannot.
The delegation strategy for health policy should recognize this reality and structure CEO engagement around high-value, high-impact moments while delegating the continuous relationship management and operational policy work to the government relations function.
CEO-level policy engagement is most valuable in: direct meetings with cabinet-level officials or senior congressional leaders on matters of material strategic importance, participation in industry coalition leadership (for example, serving on a PhRMA board committee), public testimony or advocacy on major policy issues where the CEO’s personal credibility strengthens the company’s position, and participation in policy events where CEO presence signals the company’s commitment to policy engagement.
Everything below this strategic level should be delegated to the government relations team and their external partners.
Building the Government Relations Delegation Structure
VP or SVP of Government Affairs
The head of government affairs is the CEO’s primary delegate for policy engagement. This leader should have deep relationships across the relevant policy community, strong political judgment, and the ability to represent the company’s interests effectively without CEO involvement in day-to-day interactions.
The CEO should invest in selecting and supporting a government affairs leader who is credible with senior policymakers in their own right, not just as a company representative. This credibility is built over years and is a significant organizational asset that takes time to develop.
Federal versus state versus international
For companies with significant exposure across multiple policy environments, the government affairs function may include dedicated teams for federal affairs, state affairs, and international government relations. Each of these sub-functions may have its own lead who reports to the VP of Government Affairs.
The CEO should be more directly engaged in federal affairs for the most material policy issues, less directly engaged in state affairs (unless a particular state presents an unusual strategic priority), and engaged at strategic inflection points in international government relations.
External advocacy partners
Most pharma companies retain lobbyists, law firms with regulatory expertise, and policy consulting firms to supplement internal government affairs capabilities. Managing these external relationships should be the responsibility of the VP of Government Affairs, not the CEO. The CEO’s visibility into external advocacy should come through the VP’s reporting, not through direct relationships with outside lobbyists.
Delegating Trade Association Engagement
PhRMA, BIO, and other trade associations require member companies to invest time and resources in shared policy advocacy. This can include CEO participation in governing boards, senior staff participation in working groups, and financial contributions to association activities.
The CEO should make deliberate decisions about which trade association leadership roles to accept and which to decline based on the strategic value of the association’s policy agenda to the company’s priorities. Once a decision is made to participate actively, the operational management of the company’s trade association relationships should be delegated to the VP of Government Affairs.
The CEO should receive a quarterly briefing on trade association policy priorities and any issues where the company’s position diverges from the association’s advocacy direction. Where the company has significant differences with association positions, the CEO may need to be directly involved in managing those differences at the senior leadership level of the association.
Managing Policy Risk Through the Government Relations Function
Health policy presents material financial and strategic risk for pharma companies. Drug pricing legislation, changes to Medicare Part D, international reference pricing policies, and patent reform can all affect the company’s revenue and pipeline value.
The CEO should ensure that the government relations function operates an effective policy monitoring and risk assessment process. This means:
Maintaining real-time monitoring of legislative and regulatory developments across all relevant policy domains, assessing the probability and potential financial impact of material policy changes, identifying and implementing advocacy strategies to influence policy outcomes where possible, and preparing contingency plans for adverse policy outcomes.
The CEO should receive a regular policy risk briefing (monthly or quarterly, depending on the current policy environment) that highlights the most material policy developments and risks. This briefing should be prepared by the government affairs function and should include both the policy analysis and the recommended advocacy responses.
Aligning Government Relations With Commercial and Regulatory Strategy
Government relations does not operate in isolation from the company’s commercial and regulatory activities. Market access, pricing, and reimbursement strategy are fundamentally shaped by government health policy. Regulatory affairs and FDA engagement have a government relations dimension. And commercial launches often require coordinated government affairs activity around coverage and reimbursement.
The CEO should ensure that government affairs is integrated into the company’s strategic planning and business review processes, not treated as a standalone corporate affairs function with limited operational connections to the business.
Practical integration mechanisms include including the VP of Government Affairs in key pipeline and commercial strategy reviews, ensuring government affairs input into pricing and market access decisions that will require government-facing advocacy, and coordinating government affairs and regulatory affairs activities around major regulatory submissions and advisory committee meetings.
International Government Relations: Special Delegation Considerations
For pharma companies with significant international operations, government relations extends beyond the US to encompass health ministries, national health services, and legislative bodies in key markets. The strategic and operational complexity of international government relations is substantial, and the CEO cannot maintain direct engagement across all of these environments.
The delegation approach for international government relations typically involves regional or country-level government affairs teams that operate with local expertise and relationships, coordinated by the central government affairs function. The CEO should maintain direct engagement with government officials in the two or three markets that are most strategically important, relying on the regional teams for ongoing relationship management in other markets.
For broader guidance on delegating global operations, the digital health delegation guide provides complementary perspectives on managing distributed functions. For regulatory strategy at the FDA interface, the regulatory affairs delegation guide provides detailed guidance.
The CEO as Policy Voice: Strategic Communications Integration
CEOs who are effective in health policy advocacy typically combine direct government engagement with external communications that shape the policy environment. Op-eds, conference addresses, and media engagement on policy topics can influence the narrative around key policy issues in ways that direct lobbying cannot.
The CEO’s communications team and government affairs function should work together to develop a policy communications strategy that amplifies the company’s policy positions through the CEO’s external voice. This strategy should be coordinated and deliberate rather than reactive, and the government affairs function should help ensure that the CEO’s public policy statements are accurate, strategically aligned, and do not create unintended policy complications.
Practical Delegation Framework Summary
The following framework summarizes the delegation structure for health policy and government relations:
CEO-owned: strategic policy positions, senior government official relationships, trade association board participation, major public policy statements, and material policy risk decisions.
VP of Government Affairs-owned: all operational government relations activities, lobbying programs, state and international government affairs management, trade association working group participation, external advocacy partner management, and policy monitoring and reporting.
Cross-functional coordination: government affairs and commercial/medical/regulatory alignment on market access and FDA engagement policy, coordinated through standing cross-functional governance.
Board visibility: quarterly government affairs update to the board covering material policy risks and advocacy status on key legislative and regulatory matters.
Conclusion
Health policy and government relations is a domain where pharma CEO engagement is genuinely strategic and organizationally valuable, but where the scope of that engagement must be carefully bounded. By investing in a strong government affairs function with experienced leadership, building the governance structures that keep the CEO informed without requiring operational involvement, and reserving CEO engagement for genuinely high-value policy interactions, pharma companies can build policy capability that effectively represents the company’s interests while preserving the CEO’s time for the full range of strategic leadership responsibilities.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.